AXA-042
Solid Tumors (checkpoint‑insensitive)
Phase 1Active
Key Facts
About Axelia Oncology
Australian biotech developing a systemic TLR2/6 agonist to treat checkpoint‑insensitive solid tumours.
View full company profileSolid Tumors (checkpoint‑insensitive)
Australian biotech developing a systemic TLR2/6 agonist to treat checkpoint‑insensitive solid tumours.
View full company profile